These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25427011)

  • 21. Standards for sample composition and impairment classification in neuropsychological studies of multiple sclerosis.
    Benedict R
    Mult Scler; 2009 Jul; 15(7):777-8. PubMed ID: 19542261
    [No Abstract]   [Full Text] [Related]  

  • 22. Cognitive impairment in patients with relapsing-remitting multiple sclerosis. The correlation with MRI lesion volume.
    Karlińska I; Siger M; Lewańska M; Selmaj K
    Neurol Neurochir Pol; 2008; 42(5):416-23. PubMed ID: 19105110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis.
    Goretti B; Portaccio E; Ghezzi A; Lori S; Moiola L; Falautano M; Viterbo R; Patti F; Vecchio R; Pozzilli C; Bianchi V; Cappiello S; Comi G; Trojano M; Amato MP;
    Mult Scler; 2012 Mar; 18(3):329-34. PubMed ID: 21844064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symptom clusters in women with relapsing-remitting multiple sclerosis.
    Newland PK; Fearing A; Riley M; Neath A
    J Neurosci Nurs; 2012 Apr; 44(2):66-71. PubMed ID: 22367268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Specificity of attention and cognitive inhibition processes in relapsing -remitting multiple sclerosis patients with consideration of their mood level].
    Tyburski E; Potemkowski A; Cheć M; Sołtys A; Mak M; Samochowiec A
    Psychiatr Pol; 2014; 48(2):307-18. PubMed ID: 25016768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence of age and illness duration on cognitive impairment in aging patients with relapsing-remitting multiple sclerosis (RR-MS)].
    Leclercq E; Cabaret M; Guilbert A; Jougleux C; Vermersch P; Moroni C
    Geriatr Psychol Neuropsychiatr Vieil; 2014 Sep; 12(3):331-8. PubMed ID: 25245320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis.
    Penner IK; Hubacher M; Rasenack M; Sprenger T; Weber P; Naegelin Y
    Mult Scler; 2013 Mar; 19(3):366-8. PubMed ID: 22740487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X
    Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β.
    Melanson M; Grossberndt A; Klowak M; Leong C; Frost EE; Prout M; Le Dorze JA; Gramlich C; Doupe M; Wong L; Esfahani F; Gomori A; Namaka M
    Int J Neurosci; 2010 Oct; 120(10):631-40. PubMed ID: 20942577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive deficits in multiple sclerosis patients with cerebellar symptoms.
    Valentino P; Cerasa A; Chiriaco C; Nisticò R; Pirritano D; Gioia M; Lanza P; Canino M; Del Giudice F; Gallo O; Condino F; Torchia G; Quattrone A
    Mult Scler; 2009 Jul; 15(7):854-9. PubMed ID: 19542264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].
    Patrucco L; Rojas JI; Cristiano E
    Rev Neurol; 2010 May; 50(9):529-32. PubMed ID: 20443171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A; Spada V; Beerkircher D; Kreitman RR
    Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S; Mason D
    N Z Med J; 2012 Feb; 125(1350):37-44. PubMed ID: 22382255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.